
Invivyd Inc (IVVD) Stock Forecast & Price Target
Invivyd Inc (IVVD) Analyst Ratings
Bulls say
Invivyd Inc has positioned itself favorably within the competitive biopharmaceutical landscape by receiving FDA emergency use authorization for its lead product, PEMGARDA, which addresses the critical need for COVID-19 prevention in immunocompromised individuals. The company's upcoming Phase 3 program, REVOLUTION, aims to evaluate VYD2311, potentially enhancing its market presence significantly, especially if its efficacy is demonstrated against mRNA vaccines within a larger patient population. This strategic focus on innovative monoclonal antibody therapies, including ongoing developments for RSV and other viral diseases, contributes to a strong outlook, bolstered by the substantial revenue potential of the current COVID-19 vaccine market.
Bears say
Invivyd Inc. faces significant challenges as its lead product, PEMGARDA, demonstrated a markedly diminished effectiveness against the omicron variant, with activity dropping by approximately 200-fold, indicating a potential reduction in market viability. Additionally, the concerning trend of decreasing vaccination rates for COVID-19 and influenza undermines the commercial potential for Invivyd's therapies, especially as protective levels from mRNA vaccines wane drastically among vulnerable populations such as the elderly and immunocompromised. Overall, the combination of these factors suggests a constricting market opportunity for Invivyd's monoclonal antibody therapies.
This aggregate rating is based on analysts' research of Invivyd Inc and is not a guaranteed prediction by Public.com or investment advice.
Invivyd Inc (IVVD) Analyst Forecast & Price Prediction
Start investing in Invivyd Inc (IVVD)
Order type
Buy in
Order amount
Est. shares
0 shares